Liao Fuben, Zhu Jinjin, He Junju, Liu Zheming, Yao Yi, Song Qibin
Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China.
Thorac Cancer. 2025 Jan;16(1):e15482. doi: 10.1111/1759-7714.15482. Epub 2024 Nov 18.
To search for a new biomarker that can predict the efficacy and prognosis of tumor immunotherapy.
FOXK2 genes were analyzed using single-cell sequencing in pan-cancer bulk RNA-seq from the TCGA database. We used algorithms to predict their immune infiltration. Functional enrichment and ChIP-seq identified potential downstream gene, FBXO32. FBXO32's role in cancer immune response was explored through analysis.
Significant up-regulation of FOXK2 was observed in prostate adenocarcinoma (PRAD), uterine corpus endometrial carcinoma (UCEC), bladder urothelial carcinoma (BLCA), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), and stomach adenocarcinoma (STAD), while no such increase was found in lung cancer (lung adenocarcinoma [LUAD], lung squamous cell carcinoma [LUSC]) or thyroid carcinoma (THCA) tumor and adjacent tissues. FOXK2 expression correlated with patient prognosis, with lower expression associated with better immune response and survival and higher expression of its downstream gene FBXO32 linked to worse overall survival (OS) and immune infiltration. FOXK2 has the potential to be used as a prognostic indicator and target for treatment in individuals with cancer.
Our research provides insights into the significance of FOXK2 in cancer and indicates its potential as both a prognostic indicator and target for treatment. The ribosome-associated pathways involving FOXK2 and FBXO32 could be pivotal in the advancement of tumors, offering possible avenues for targeted and individualized immunotherapy approaches. Additional research is required to completely understand the mechanisms that are responsible for the participation of FOXK2 and its subsequent gene FBXO32 in cancer, as well as to explore the possible advantages of focusing on FOXK2 for cancer treatment.
寻找一种能够预测肿瘤免疫治疗疗效和预后的新型生物标志物。
利用TCGA数据库中泛癌批量RNA测序的单细胞测序分析FOXK2基因。我们使用算法预测其免疫浸润情况。功能富集和ChIP-seq鉴定出潜在的下游基因FBXO32。通过分析探索FBXO32在癌症免疫反应中的作用。
在前列腺腺癌（PRAD）、子宫内膜癌（UCEC）、膀胱尿路上皮癌（BLCA）、结直肠癌（CRC）、胰腺导管腺癌（PDAC）和胃腺癌（STAD）中观察到FOXK2显著上调，而在肺癌（肺腺癌[LUAD]、肺鳞状细胞癌[LUSC]）或甲状腺癌（THCA）的肿瘤及癌旁组织中未发现这种增加。FOXK2表达与患者预后相关，较低表达与更好的免疫反应和生存相关，其下游基因FBXO32的较高表达与较差的总生存期（OS）和免疫浸润相关。FOXK2有潜力作为癌症患者的预后指标和治疗靶点。
我们的研究揭示了FOXK2在癌症中的重要性，并表明其作为预后指标和治疗靶点的潜力。涉及FOXK2和FBXO32的核糖体相关途径可能在肿瘤进展中起关键作用，为靶向和个体化免疫治疗方法提供了可能的途径。需要进一步研究以全面了解FOXK2及其后续基因FBXO32参与癌症的机制，以及探索专注于FOXK2进行癌症治疗的潜在优势。
